---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-09-06T14:39:37.842001'
end_time: '2026-09-06T14:59:29.204996'
duration_seconds: 1191.36
template_file: templates/disease_pathophysiology_research.md
template_sha: "1e7ea4ee817acfe1dda5f77fafe6f2e8b5927666"
template_variables:
  disease_name: Jervell and Lange-Nielsen Syndrome 2
  mondo_id: MONDO:0012871
  category: Mendelian
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
    save_artifacts: true
    artifact_max_bytes: 5242880
citation_count: 19
reference_validation:
  total_references: 19
  verified: 19
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 19
  on_topic: 14
  validator_version: 0.2.1
term_validation:
  total_terms: 22
  verified: 20
  not_found: 0
  obsolete: 0
  unverifiable: 2
  confabulation_rate: 0.0
  labels_checked: 9
  labels_matching: 6
  labels_mismatched: 3
  mislabelled_terms:
  - term_id: MONDO:0012871
    reported_labels:
    - MONDO
    ontology_label: Jervell and Lange-Nielsen syndrome 2
  - term_id: UBERON:0002282
    reported_labels:
    - organ of Corti
    ontology_label: stria vascularis of cochlear duct
  - term_id: UBERON:0002295
    reported_labels:
    - stria vascularis
    ontology_label: scala media
  unresolvable_prefixes:
  - ORPHA
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: Jervell_and_Lange-Nielsen_Syndrome_2-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: Jervell_and_Lange-Nielsen_Syndrome_2-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Jervell and Lange-Nielsen Syndrome 2
- **MONDO ID:** MONDO:0012871 (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Jervell and Lange-Nielsen Syndrome 2** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Jervell and Lange-Nielsen Syndrome Type 2 (JLNS2): Comprehensive Disease Characteristics Report

**Disease:** Jervell and Lange-Nielsen Syndrome 2 (JLNS2)
**MONDO ID:** MONDO:0012871 · **OMIM:** #612347 · **Category:** Mendelian (autosomal recessive)
**Causal gene:** *KCNE1* (HGNC:6240; chr21q22.12)

---

## Summary

Jervell and Lange-Nielsen syndrome type 2 (JLNS2) is a rare, autosomal-recessive **cardioauditory ion channelopathy** defined by the combination of **congenital profound bilateral sensorineural deafness** and **severe long QT syndrome (LQTS)** with a high risk of life-threatening ventricular arrhythmia and sudden cardiac death from early childhood. It is the minority molecular form of Jervell and Lange-Nielsen syndrome (JLNS): approximately 90% of JLNS is caused by biallelic *KCNQ1* variants (JLNS1), while JLNS2 is caused by biallelic loss-of-function variants in **KCNE1**, the gene encoding the minK/IsK β-subunit of the slowly activating delayed-rectifier potassium channel **IKs**.

The unifying mechanism is loss of IKs function in two tissues that critically depend on it. In the **cochlea**, the KCNQ1/KCNE1 complex in marginal cells of the stria vascularis secretes K⁺ into the endolymph; its loss collapses endolymph production and the endocochlear potential, causing degeneration of the organ of Corti and congenital deafness together with vestibular dysfunction. In the **heart**, loss of IKs removes ventricular "repolarization reserve," prolonging the action potential and QT interval, promoting early afterdepolarizations, torsades de pointes, and sudden death. A single β-subunit defect thus explains both cardinal features of the disease.

Clinically, JLNS carries a very high, early-onset cardiac-event burden (≈93% cumulative cardiac events by age 40, mean onset ~5 years), markedly worse than autosomal-dominant Romano-Ward syndrome. Beta-blocker monotherapy is insufficient (~35% LQTS-related mortality in one prospective cohort), whereas implantable cardioverter-defibrillator (ICD) therapy dramatically improves survival. Cochlear implantation restores hearing but demands rigorous perioperative arrhythmia precautions, and inner-ear gene therapy has shown preclinical promise in *Kcne1*-deficient mice. This report consolidates six confirmed findings across disease information, etiology, phenotypes, molecular genetics, mechanism, epidemiology, diagnostics, prognosis, treatment, prevention, and model organisms, and honestly documents where evidence (e.g., human molecular-profiling data) is absent.

---

## 1. Disease Information

**Overview.** JLNS2 is a Mendelian cardioauditory syndrome combining (i) congenital, profound, bilateral sensorineural hearing loss and (ii) a markedly prolonged QT interval predisposing to syncope, torsades de pointes, and sudden cardiac death. It is one of two molecular subtypes of Jervell and Lange-Nielsen syndrome, first described clinically by Jervell and Lange-Nielsen in 1957 as familial deafness with QT prolongation and sudden death.

**Key identifiers.**

| Resource | Identifier |
|---|---|
| MONDO | MONDO:0012871 |
| OMIM | #612347 (JERVELL AND LANGE-NIELSEN SYNDROME 2; JLNS2) |
| Gene | *KCNE1* (HGNC:6240; NCBI Gene 3753; Ensembl ENSG00000180509) |
| Orphanet | ORPHA:90647 (Jervell and Lange-Nielsen syndrome) |
| ICD-10 | I45.81 (Long QT syndrome) / related cardioauditory coding |
| MeSH | D029593 (Jervell-Lange Nielsen Syndrome) |

**Synonyms / alternative names.** Jervell and Lange-Nielsen syndrome type 2; cardioauditory syndrome of Jervell and Lange-Nielsen (KCNE1 type); surdocardiac syndrome; long QT syndrome type 5 with deafness (JLNS2 is the recessive, deafness-associated allelic counterpart of *KCNE1*-related LQT5). Note: heterozygous *KCNE1* variants are associated with **Romano-Ward syndrome / LQT5** without deafness.

**Data provenance.** The information in this report is derived from **aggregated disease-level resources** (OMIM, Orphanet, ClinVar, gnomAD) and **primary literature** (case series, family studies, an international registry cohort, and animal models) — not from individual EHR records.

---

## 2. Etiology

**Primary cause — genetic.** JLNS2 is caused by **biallelic (homozygous or compound heterozygous) loss-of-function variants in *KCNE1***. Faridi et al. (2019) described three homozygous nonsense mutations of *KCNE1* — c.50G>A (p.Trp17*), c.51G>A (p.Trp17*), and c.138C>A (p.Tyr46*) — segregating in families ascertained for sensorineural deafness, establishing biallelic null *KCNE1* as causal for JLNS2 [PMID: 30461122].

> *"biallelic truncating null variants of KCNE1 that have not been previously reported. We describe three homozygous nonsense mutations of KCNE1 segregating in families ascertained ostensibly for nonsyndromic deafness: c.50G>A (p.Trp17*), c.51G>A (p.Trp17*), and c.138C>A (p.Tyr46*)"* — Faridi et al., 2019 [PMID: 30461122]

**Genetic risk factors.** The essential (and only established necessary) risk factor is inheritance of two loss-of-function *KCNE1* alleles. **Consanguinity** is a major population-level risk factor because it raises homozygosity for rare recessive null alleles — JLNS and homozygous LQTS are enriched in consanguineous populations (e.g., Saudi Arabia, Pakistan) [PMID: 28438721; PMID: 22830134].

**Environmental risk factors (arrhythmia triggers, not disease-causing).** Because the cardiac substrate is fixed by genotype, "risk factors" in JLNS2 are really **triggers of arrhythmic events**: adrenergic/sympathetic stimulation (exercise, emotion, startle/auditory stimuli, fright), **anesthesia and QT-prolonging drugs**, and the perioperative period (notably cochlear implantation). More than 25% of JLNS patients experience sudden cardiac death, with triggers including anesthesia [PMID: 32508908].

**Protective factors.** No natural genetic protective alleles are established for JLNS2. Protective *interventions* (below in Treatment/Prevention) include beta-blockade, ICDs, atrial pacing, avoidance of QT-prolonging drugs, and left cardiac sympathetic denervation.

**Gene–environment interactions.** The genotype sets the substrate (loss of repolarization reserve); environmental **sympathetic triggers** precipitate torsades de pointes on that substrate. This is the paradigmatic gene–environment interaction in JLNS2 and dictates its management (beta-blockers to blunt adrenergic drive; avoiding QT-prolonging drugs).

---

## 3. Phenotypes

JLNS2 has two cardinal phenotype domains — **auditory/vestibular** and **cardiac** — both congenital.

| Phenotype | Type | Onset | Severity | Frequency | Suggested HPO |
|---|---|---|---|---|---|
| Bilateral sensorineural hearing loss | Physical/sensory sign | Congenital | Profound, stable | ~100% (defining) | HP:0000407 (Sensorineural hearing impairment); HP:0008527 (Congenital SNHL) |
| Prolonged QT interval | Laboratory/ECG abnormality | Congenital | Severe (QTc often ≥500–550 ms) | ~100% (defining) | HP:0001657 (Prolonged QT interval) |
| Syncope | Symptom | Early childhood | Severe, episodic | Very common | HP:0001279 (Syncope) |
| Torsades de pointes / ventricular arrhythmia | Clinical sign | Early childhood | Life-threatening, episodic | Very common | HP:0004308 (Ventricular arrhythmia); HP:0031547 (Torsade de pointes) |
| Sudden cardiac death | Outcome | Childhood onward | Fatal | >25% of JLNS | HP:0001645 (Sudden cardiac death) |
| Vestibular dysfunction | Sign | Congenital | Variable | Common (KCNE1) | HP:0002321 (Vertigo); vestibular areflexia |

**Auditory phenotype.** Congenital, profound, bilateral **sensorineural** hearing loss is present from birth and is stable (non-progressive) once established, reflecting a developmental/homeostatic failure of endolymph production rather than a degenerative course. Vestibular (balance) dysfunction accompanies the hearing loss in *KCNE1* disease [PMID: 33514733; PMID: 34744965].

> *"Mutations in voltage-gated potassium channel KCNE1 cause Jervell and Lange-Nielsen syndrome type 2 (JLNS2), resulting in congenital deafness and vestibular dysfunction"* — Wu et al., 2021 [PMID: 33514733]

**Cardiac phenotype.** Marked QT prolongation (mean QTc ~548 ± 73 ms in JLNS vs 500 ± 48 ms in Romano-Ward), syncope, torsades de pointes, and high risk of sudden death beginning in early childhood [PMID: 16911578].

**Quality-of-life impact.** The dual sensory-plus-cardiac burden is substantial: profound deafness impairs language, education, and social development (mitigated by cochlear implantation), while the arrhythmia risk imposes activity restriction, chronic medication, device implantation, and psychological burden on children and families. Disease-specific QoL instruments for JLNS2 are not established in the literature reviewed.

---

## 4. Genetic / Molecular Information

**Causal gene.** ***KCNE1*** (potassium voltage-gated channel subfamily E regulatory subunit 1; minK/IsK). Location: chr21q22.12 (GRCh38 chr21:34,446,688–34,512,214). Canonical transcript ENST00000399286; the coding region is a single short exon (~129 aa protein), which is important for interpreting population constraint (below).

**Pathogenic variants.**
- **Variant classes causing JLNS2:** biallelic **loss-of-function** — nonsense/truncating (e.g., p.Trp17*, p.Tyr46*), frameshift, and loss-of-function missense — inherited homozygously or as compound heterozygotes [PMID: 30461122]. Case reports also document *KCNE1* missense variants (e.g., an A→G missense) in JLNS2 patients [PMID: 33040543].
- **Classification (ACMG/AMP):** truncating null variants segregating with disease are classified pathogenic/likely pathogenic; certain missense variants are pathogenic via a dominant-negative mechanism (see Romano-Ward, below).
- **Functional consequence:** loss of function of the minK β-subunit → reduced/absent IKs current.

**Genotype–phenotype spectrum (a central molecular insight).**

| Genotype | Mechanism | Phenotype |
|---|---|---|
| Biallelic (homozygous/compound-het) null *KCNE1* | Complete IKs loss | **JLNS2**: deafness + severe LQT |
| Heterozygous null *KCNE1* | Haploinsufficiency tolerated | Often **normal QT**; may be silent |
| Heterozygous dominant-negative missense *KCNE1* | Mutant minK poisons WT KCNQ1/KCNE1 complexes | **Romano-Ward / LQT5** (no deafness) |

> *"heterozygotes for loss-of-function variants of KCNE1 may have normal QT intervals while biallelic null alleles are associated with JLNS2, indicating a complex genotype-phenotype spectrum for KCNE1 variants"* — Faridi et al., 2019 [PMID: 30461122]

> *"Coassembly of certain mutant KCNE1 monomers with wild-type KCNQ1 subunits results in RWS by a dominant negative mechanism"* — Faridi et al., 2019 [PMID: 30461122]

**Population constraint (gnomAD) explains the split.** gnomAD constraint metrics for *KCNE1* show it is **loss-of-function tolerant but strongly missense-constrained**: pLI = 0.36, observed/expected LoF = 0.34 (obs 1 vs exp 2.93; wide CI 0.12–1.62 reflecting the tiny single-exon coding region), while missense o/e = 0.30 with **missense Z = 3.67** (obs 45 vs exp 150). In plain terms, heterozygous null alleles are tolerated in the general population (consistent with recessive inheritance of JLNS2), whereas missense variants are under strong purifying selection (consistent with dominant-negative missense variants causing Romano-Ward). This constraint pattern is a molecular mirror of the clinical genotype–phenotype dichotomy.

**Modifier genes.** In malignant/atypical JLNS cases, additional cardiac-panel variants (e.g., *RYR2*, *NKX2-5*) have been proposed as modifiers of disease severity, supporting the value of broad targeted panels [PMID: 29037160]. Note: that particular case had a *KCNQ1* (JLNS1) primary lesion, but the principle of oligogenic modification is relevant to JLNS2 as well.

**Epigenetic information.** No JLNS2-specific DNA-methylation or histone-modification data were identified — this is a knowledge gap.

**Chromosomal abnormalities.** JLNS2 is a single-gene disorder; large structural/aneuploidy causes are not implicated (*KCNE1* is on 21q22.12, within the Down-syndrome-critical region, but JLNS2 arises from point/small variants, not trisomy 21).

---

## 5. Environmental Information

- **Environmental/toxic factors:** No environmental cause of the disease itself. **QT-prolonging drugs** (many antiarrhythmics, macrolides, antipsychotics, some antiemetics) are the key iatrogenic hazard that worsens the substrate.
- **Lifestyle factors:** Strenuous/competitive exercise, swimming, and situations of intense emotion or startle can trigger events; activity modification is standard advice.
- **Infectious agents:** Not applicable — JLNS2 is not infectious. (Febrile illness/electrolyte disturbance can secondarily aggravate QT but are not causal.)

---

## 6. Mechanism / Pathophysiology

### Ordered causal chain

**Cardiac branch:**
1. Biallelic loss-of-function *KCNE1* variants **result in** absent/nonfunctional minK (IsK) β-subunits.
2. Loss of minK **leads to** failure of KCNQ1/KCNE1 co-assembly and **markedly reduced IKs** (slow delayed-rectifier K⁺ current). *(Demonstrated in heterologous expression and knockout models.)*
3. Reduced IKs **results in** loss of ventricular **repolarization reserve** and **prolongation of the cardiac action potential**.
4. Action-potential prolongation **leads to** QT-interval prolongation on ECG and predisposition to **early afterdepolarizations**.
5. Early afterdepolarizations plus increased transmural dispersion of repolarization **result in** **torsades de pointes**, which can degenerate to ventricular fibrillation. *(Dispersion-of-repolarization mechanism inferred from LQT mouse mapping studies [PMID: 19148726].)*
6. Ventricular fibrillation **leads to** syncope and **sudden cardiac death**, precipitated by adrenergic triggers.

**Auditory/vestibular branch:**
1. Loss of IKs in **marginal cells of the stria vascularis** (cochlea) and vestibular dark cells **results in** failure of K⁺ secretion into the **endolymph**.
2. Failed K⁺ secretion **leads to** collapse of the **endocochlear potential** and endolymphatic compartment.
3. Loss of endolymph homeostasis **results in** degeneration of the **organ of Corti** and **spiral ganglion**, and **atrophy of the stria vascularis**. *(Demonstrated in Kcnq1 knockout mice modeling JLNS [PMID: 15891643].)*
4. Sensory epithelial degeneration **leads to** congenital profound sensorineural deafness and vestibular dysfunction.

### Detail

**Molecular pathway / channel biology.** The IKs channel is a hetero-oligomer of pore-forming **KCNQ1 (Kv7.1)** α-subunits and **KCNE1 (minK)** β-subunits. minK is essential for the slow activation kinetics and increased current amplitude that characterize IKs. Structural and modeling work shows that KCNQ1 assembles with KCNE1 to generate IKs, and that mutation-induced destabilization is a common cause of channel dysfunction [PMID: 31518351; PMID: 33963564].

**Protein dysfunction.** Truncating *KCNE1* variants (p.Trp17*, p.Tyr46*) yield no functional β-subunit → simple loss of function → recessive disease. Certain missense variants produce a folded but poison-subunit that co-assembles with WT KCNQ1 to exert a **dominant-negative** effect → Romano-Ward when heterozygous [PMID: 30461122].

**Biochemical abnormality.** The core defect is an **ion-channel defect** (potassium channel β-subunit deficiency), reducing outward repolarizing K⁺ current.

**Cell types & biological processes.** Cardiac ventricular cardiomyocytes (repolarization); cochlear stria vascularis marginal cells and vestibular dark cells (endolymph K⁺ secretion). Suggested ontology terms: **GO:0086009** (membrane repolarization), **GO:1990573** (potassium ion import across plasma membrane), **GO:0042472** (inner ear morphogenesis)/endolymph homeostasis; **CL:0000746** (cardiac muscle cell), stria vascularis marginal epithelial cells.

**Molecular profiling (transcriptomics/proteomics/metabolomics).** No human JLNS2-specific omics datasets were identified in this investigation — an honest gap. Mechanistic knowledge derives from electrophysiology, structural modeling, and mouse knockouts rather than patient-tissue profiling.

---

## 7. Anatomical Structures Affected

- **Organ level (primary):** **Heart** (ventricular myocardium — cardiovascular system) and **inner ear** (cochlea and vestibular apparatus — nervous/sensory system). UBERON:0000948 (heart); UBERON:0001846 (internal ear); UBERON:0002282 (organ of Corti); UBERON:0002295 (stria vascularis).
- **Secondary involvement:** Central nervous system consequences of cerebral hypoperfusion during arrhythmia (syncope, potential anoxic injury/seizure-like events); developmental impact of deafness.
- **Tissue/cell level:** Cardiac muscle (ventricular cardiomyocytes; CL:0000746); cochlear/vestibular epithelium — **stria vascularis marginal cells** and vestibular dark cells; secondary loss of cochlear hair cells (CL:0000855) and spiral ganglion neurons (CL:0000100).
- **Subcellular level:** Plasma-membrane voltage-gated potassium channel complex (GO:0008076, voltage-gated potassium channel complex); sarcolemma of cardiomyocytes; apical/basolateral membranes of strial marginal cells.
- **Localization / lateralization:** Bilateral, symmetric involvement of both inner ears; global ventricular repolarization abnormality.

---

## 8. Temporal Development

- **Onset:** Congenital for both deafness (present at birth) and the QT abnormality. Cardiac symptoms (syncope, arrhythmia) typically begin in **early childhood** — mean age of first cardiac event ~5.0 years in JLNS [PMID: 16911578].
- **Onset pattern:** Chronic underlying substrate with **episodic** acute arrhythmic events.
- **Progression:** The hearing loss is **stable/non-progressive** once congenitally established. The cardiac risk is **lifelong and high**, with events clustering in childhood and adolescence.
- **Disease course:** Chronic, lifelong; punctuated by potentially fatal arrhythmic episodes.
- **Critical periods / intervention windows:** Early childhood (peak event risk) is the critical window for risk stratification and ICD consideration; the **perioperative period** of cochlear implantation is a discrete high-risk window requiring specific precautions.

---

## 9. Inheritance and Population

**Inheritance.** Autosomal **recessive** — requires biallelic *KCNE1* loss-of-function. Heterozygous carriers are typically asymptomatic with normal or near-normal QT (in contrast to dominant-negative missense carriers who have Romano-Ward) [PMID: 30461122].

**Penetrance / expressivity.** For the biallelic-null genotype, penetrance of the JLNS2 phenotype (deafness + LQT) is essentially complete, though cardiac event severity is variable. No genetic anticipation (not a repeat-expansion disorder).

**Epidemiology.** JLNS (both subtypes combined) is very rare, with worldwide prevalence estimated at **~1/1,000,000 to 1/200,000** [PMID: 32508908]. Approximately **90% of JLNS is JLNS1 (KCNQ1)**; JLNS2 (KCNE1) is the **minority** subtype [PMID: 32508908]. ECG screening of deaf children yields JLNS in a measurable fraction — e.g., 4/440 (0.9%) congenitally deaf children in an Istanbul screening study [PMID: 34308870], and significant prevalence among Pakistani deaf-mute children linked to high consanguinity [PMID: 22830134].

> *"The prevalence of JLNS is about 1/1000000 to 1/200000 around the world. However, exceed 25% of JLNS patients suffered sudden cardiac death with kinds of triggers containing anesthesia"* — Qiu et al., 2020 [PMID: 32508908]

> *"A total of 8 patients were found with a prolonged QT interval. JLNS was diagnosed in 4 (0.9%) patients"* — Ergül et al., 2021 [PMID: 34308870]

**Founder effects / consanguinity.** Enriched in **consanguineous populations** (Middle East, South Asia). A Saudi LQTS cohort found homozygous mutations in a majority of probands, with congenital deafness in ~48% of homozygous probands — underscoring the consanguinity contribution [PMID: 28438721].

**Sex ratio.** No strong sex predilection is established for JLNS2 (recessive; both sexes equally affected).

**Carrier frequency.** Not precisely defined for JLNS2; heterozygous *KCNE1* LoF alleles are tolerated in gnomAD (LoF-tolerant constraint), consistent with rare recessive disease.

---

## 10. Diagnostics

**Clinical / electrophysiology.**
- **ECG (12-lead):** cornerstone — reveals marked QT/QTc prolongation (often ≥500–550 ms); T-wave abnormalities; documentation of torsades de pointes. QTc computed by Bazett's formula; Schwartz criteria used for LQTS probability [PMID: 22830134].
- **Holter / ambulatory ECG:** quantify QT dynamics and capture arrhythmia.
- **Audiology:** audiometry/ABR confirming profound bilateral sensorineural hearing loss; vestibular testing may reveal peripheral vestibular loss [PMID: 34744965].
- **Imaging:** inner-ear imaging (CT/MRI) is typically **normal** in JLNS — notably **no inner-ear malformations**, which distinguishes it from some other syndromic deafness (important for cochlear-implant planning) [PMID: 39210075].

**Genetic testing (confirmatory).**
- Recommended approach: molecular confirmation of **biallelic *KCNE1*** variants (with *KCNQ1* tested in parallel, since ~90% of JLNS is JLNS1). Options include LQTS/cardiac **gene panels** (which reliably include *KCNQ1*, *KCNE1*, *KCNH2*, *SCN5A*, etc.), targeted single-gene testing when a familial variant is known, and **WES/WGS** for atypical presentations. Broad cardiac panels can also reveal severity modifiers (e.g., *RYR2*, *NKX2-5*) [PMID: 29037160].
- Family/cascade screening of relatives is valuable, especially in consanguineous families [PMID: 28438721].

**Clinical criteria / differential diagnosis.**
- **Diagnostic combination:** congenital sensorineural deafness + prolonged QT → JLNS; molecular subtyping (KCNE1 vs KCNQ1) distinguishes JLNS2 from JLNS1.
- **Differential:** Romano-Ward syndrome/LQT5 (KCNE1 heterozygous, **no deafness**); other syndromic deafness (Waardenburg, Usher, Pendred — distinguished by associated features and, for JLNS, the QT interval); acquired/drug-induced long QT.

**Screening.** ECG screening of children with congenital sensorineural deafness is an effective case-finding strategy to detect JLNS before a sentinel cardiac event [PMID: 34308870; PMID: 22830134].

---

## 11. Outcome / Prognosis

JLNS has a **poor natural history** without adequate cardiac therapy and is one of the highest-risk congenital LQTS phenotypes.

| Metric | JLNS | Romano-Ward (RWS) | Source |
|---|---|---|---|
| Mean QTc | 548 ± 73 ms | 500 ± 48 ms (P<0.001) | [PMID: 16911578] |
| Cumulative cardiac events, birth–age 40 | **93%** (mean age 5.0 ± 7.0 yr) | 54% (mean age 14.2 ± 9.3 yr) | [PMID: 16911578] |
| LQTS-related death on beta-blockers | **35%** | lower | [PMID: 16911578] |
| Mortality with defibrillator therapy | **0%** (over 4.9 ± 3.4 yr) | — | [PMID: 16911578] |
| Sudden cardiac death (overall JLNS) | **>25%** | — | [PMID: 32508908] |

> *"The cumulative rates of cardiac events from birth through age 40 among JLNS and RWS patients were 93% (mean [±SD] age: 5.0 ± 7.0 years) and 54% (mean [±SD] age: 14.2 ± 9.3 years), respectively (P < 0.001)"* — Goldenberg et al., 2006 [PMID: 16911578]

> *"Among JLNS patients treated with beta-blockers, the cumulative probability of LQTS-related death was 35%; defibrillator therapy was associated with a 0% mortality rate"* — Goldenberg et al., 2006 [PMID: 16911578]

**Prognostic factors.** Baseline **QTc ≥550 ms** confers the highest risk (hazard ratio ~15.8 vs RWS); early symptom onset and history of cardiac arrest are adverse markers. **Morbidity** derives from both recurrent syncope/arrhythmia and lifelong profound deafness (largely rehabilitated by cochlear implants).

---

## 12. Treatment

Management targets the cardiac risk (life-preserving) and the sensory deficit (rehabilitative).

**Pharmacotherapy.**
- **Beta-blockers** (e.g., propranolol, nadolol) — first-line to blunt adrenergic triggers (NCIT: Beta-Adrenergic Blocker). However, **monotherapy is insufficient in JLNS** (~35% LQTS-related death) [PMID: 16911578].
- Avoidance of **QT-prolonging drugs**; correction of electrolytes; magnesium for acute torsades.

**Device / interventional.**
- **Implantable cardioverter-defibrillator (ICD)** — associated with 0% mortality in the registry cohort and is central to secondary prevention in high-risk JLNS (NCIT: Implantable Cardioverter-Defibrillator) [PMID: 16911578].
- **Atrial pacing combined with increased beta-blocker doses** — in 6 very young JLNS patients (too small for ICD), this achieved event-free survival over 7 years [PMID: 27451284].
- **Left cardiac sympathetic denervation (LCSD)** — for breakthrough events despite beta-blockade [PMID: 18606002].
- **Radiofrequency catheter ablation** of a triggering premature ventricular contraction eliminated electrical storm in a JLNS2 patient (KCNE1 missense) with 12-month event-free follow-up — a niche option when ICD is unavailable [PMID: 33040543].

**Auditory rehabilitation.**
- **Cochlear implantation (CI)** restores useful hearing; JLNS patients typically have **no inner-ear malformation**, favoring implantation, though JLNS is among the commonest syndromic indications in CI cohorts [PMID: 39210075]. CI in these children shows meaningful auditory-performance gains (CAP/SIR improvement) [PMID: 31846911].
- **Perioperative arrhythmia precautions are mandatory** (see Prevention).

**Pharmacogenomics / advanced therapeutics.** No JLNS2-specific pharmacogenomic guidance is established. **Gene therapy** is preclinical: canalostomy-based inner-ear gene delivery preserved auditory and vestibular function in *Kcne1*-deficient mice [PMID: 33514733].

---

## 13. Prevention

- **Primary prevention:** Not preventable at the genomic level once biallelic variants are inherited. **Genetic counseling** and **carrier/cascade screening** in consanguineous families reduce recurrence risk; prenatal/preimplantation testing is possible when familial variants are known [PMID: 28438721].
- **Secondary prevention (early detection):** **ECG screening of congenitally deaf children** to identify JLNS before a first cardiac event [PMID: 34308870; PMID: 22830134].
- **Tertiary prevention (avoiding complications):** beta-blockers, ICD/atrial pacing, avoidance of QT-prolonging drugs and competitive sports, and rigorous **perioperative protocols** for cochlear implantation.

**Perioperative cochlear-implant safety pathway.** Because sympathetic stimulation and QT-prolonging anesthetics can trigger fatal arrhythmias, evidence-based multidisciplinary pathways are essential. In one comprehensive series of 41 pediatric long-QT CI patients using prophylactic beta-blockers, avoidance of sympathetic stimulation and QT-prolonging drugs, magnesium sulphate, and defibrillator standby, **fatal arrhythmias occurred intraoperatively in 5 patients and were successfully rescued by cardiac pacing**, with good hearing outcomes [PMID: 31846911]. A prior perioperative death led one program to pause CI for cLQTS until an evidence-based care pathway was introduced [PMID: 30227792].

> *"Fatal Arrhythmias were encountered intra-operatively in five patients which was treated with cardiac pacing"* — Anto et al., 2019 [PMID: 31846911]

> *"No arrhythmic events occurred in 6 very young JLNS patients who received atrial pacing in combination with increased doses of beta-blockers during 7-year follow-up"* — Früh et al., 2016 [PMID: 27451284]

---

## 14. Other Species / Natural Disease

- **Taxonomy / orthologs:** *KCNE1* is conserved across mammals; mouse ortholog *Kcne1* (minK/IsK), NCBI Gene 16506 (Mus musculus, NCBI Taxon 10090).
- **Natural disease:** No well-characterized spontaneous JLNS2 equivalent in companion animals is documented in the reviewed literature; the disease is studied primarily through engineered models.
- **Comparative biology:** The IKs (KCNQ1/KCNE1) repolarization mechanism and strial endolymph-secretion role are conserved between mouse and human, making rodents faithful models of both the cardiac and cochlear phenotypes (with caveats below).

---

## 15. Model Organisms

- **Kcne1 (minK) knockout mouse:** the principal JLNS2 model. Loss of minK produces marked IKs reduction and recapitulates the **inner-ear phenotype** (deafness, circling/vestibular dysfunction) and provides the platform for gene-therapy rescue [PMID: 33514733; PMID: 19148726].
- **Kcnq1 knockout mouse (JLNS model):** deaf, circling behavior, **atrophy of the stria vascularis, contraction of endolymphatic compartments, complete degeneration of the organ of Corti and spiral ganglion** — the definitive histopathologic demonstration of the deafness mechanism shared by JLNS1/JLNS2 [PMID: 15891643].

> *"They exhibited a marked atrophy of the stria vascularis, contraction of the endolymphatic compartments, and collapse and adhesion of surrounding membranes. There was a complete degeneration of the organ of Corti and an associated degeneration of the spiral ganglion"* — Rivas & Francis, 2005 [PMID: 15891643]

- **Model limitations (cardiac):** Mouse ventricular repolarization relies on different dominant K⁺ currents than human; consequently *minK⁻/⁻* mice show a robust **inner-ear** phenotype but a **weaker cardiac arrhythmia** phenotype (similar action-potential durations, no spontaneous arrhythmia in one optical-mapping study), whereas *Merg1⁺/⁻* (IKr) mice show clearer arrhythmia. This species difference limits mouse modeling of the human LQT phenotype [PMID: 19148726].
- **Applications:** endolymph homeostasis, stria-vascularis biology, and inner-ear gene-therapy proof-of-concept (canalostomy delivery) [PMID: 33514733]. Human iPSC-derived cardiomyocytes (not JLNS2-specific in the reviewed set) are the natural complement for modeling the cardiac electrophysiology.

---

## Mechanistic Model / Interpretation

```
          Biallelic LOF KCNE1 (minK β-subunit absent/nonfunctional)
                                  |
                     Failure of KCNQ1/KCNE1 co-assembly
                                  |
                         ↓↓ IKs (slow delayed-rectifier K+)
                       /                                 \
        CARDIAC BRANCH                                  COCHLEAR/VESTIBULAR BRANCH
        (ventricular myocytes)                          (stria vascularis marginal cells,
                |                                         vestibular dark cells)
   Loss of repolarization reserve                        Failed K+ secretion into endolymph
                |                                                 |
   Prolonged action potential -> QT up                  Collapse of endocochlear potential
                |                                                 |
   Early afterdepolarizations,                          Degeneration of organ of Corti,
   dispersion of repolarization                          spiral ganglion; strial atrophy
                |                                                 |
   Torsades de pointes -> VF                             Congenital profound SNHL
                |                                         + vestibular dysfunction
   Syncope / SUDDEN CARDIAC DEATH                        (stable, non-progressive)
   (adrenergic/anesthetic triggers)

   THERAPY:  Beta-blockers (insufficient alone) -> ICD / atrial pacing -> LCSD / ablation
   HEARING:  Cochlear implant (+ strict perioperative protocol); gene therapy (preclinical)
```

The elegance of JLNS2 is that **a single β-subunit lesion produces a two-organ disease** because the same IKs channel is indispensable for (1) ventricular repolarization and (2) cochlear/vestibular endolymph secretion. The recessive inheritance, the LoF-tolerant/missense-constrained gnomAD signature, and the Romano-Ward-vs-JLNS2 dichotomy all reconcile into one coherent picture: **null alleles need two hits to cause disease (recessive JLNS2), while dominant-negative missense alleles poison the channel with one hit (dominant Romano-Ward, no deafness because one functional allele suffices for the cochlea).**

---

## Evidence Base

| PMID | Study | Contribution |
|---|---|---|
| [30461122](https://pubmed.ncbi.nlm.nih.gov/30461122/) | Faridi et al. — *KCNE1* mutational/phenotypic spectra | Establishes biallelic null *KCNE1* as causal for JLNS2; defines recessive-null vs dominant-negative-missense mechanism |
| [16911578](https://pubmed.ncbi.nlm.nih.gov/16911578/) | Goldenberg et al. — JLNS clinical course (International LQTS Registry) | Quantifies severe prognosis; ICD superiority over beta-blockers |
| [15891643](https://pubmed.ncbi.nlm.nih.gov/15891643/) | Rivas & Francis — *Kcnq1* KO mouse inner ear | Histopathologic mechanism of deafness (strial/organ-of-Corti degeneration) |
| [33514733](https://pubmed.ncbi.nlm.nih.gov/33514733/) | Wu et al. — canalostomy gene therapy in *Kcne1* mouse | Confirms KCNE1→JLNS2 with vestibular involvement; preclinical gene-therapy rescue |
| [32508908](https://pubmed.ncbi.nlm.nih.gov/32508908/) | Qiu et al. — JLNS case + review | Prevalence (~1/1,000,000–1/200,000); >25% SCD; ~90% KCNQ1 |
| [34308870](https://pubmed.ncbi.nlm.nih.gov/34308870/) | Ergül et al. — deaf-child ECG screening | JLNS prevalence among congenitally deaf children (0.9%) |
| [31846911](https://pubmed.ncbi.nlm.nih.gov/31846911/) | Anto et al. — CI in long-QT children | Intraoperative arrhythmia risk and pacing rescue during CI |
| [27451284](https://pubmed.ncbi.nlm.nih.gov/27451284/) | Früh et al. — atrial pacing + beta-blockade | Effective strategy in very young JLNS patients |
| [28438721](https://pubmed.ncbi.nlm.nih.gov/28438721/) | Saudi LQTS cohort | Consanguinity, homozygosity, deafness enrichment |
| [22830134](https://pubmed.ncbi.nlm.nih.gov/22830134/) | Pakistani deaf-mute screening | Consanguinity-linked JLNS prevalence |
| [19148726](https://pubmed.ncbi.nlm.nih.gov/19148726/) | Arrhythmia phenotype in LQT mice | Dispersion-of-repolarization mechanism; mouse cardiac-model limitation |
| [30227792](https://pubmed.ncbi.nlm.nih.gov/30227792/) | Scott-Warren et al. — CI care pathway | Perioperative death → evidence-based pathway |
| [39210075](https://pubmed.ncbi.nlm.nih.gov/39210075/) | Syndromic CI cohort | JLNS common CI indication; no inner-ear malformation |
| [31518351](https://pubmed.ncbi.nlm.nih.gov/31518351/) | KCNQ1 structural models | IKs assembly; destabilization as dysfunction mechanism |
| [33040543](https://pubmed.ncbi.nlm.nih.gov/33040543/) | Ablation of triggering PVC in JLNS2 | Niche cardiac option; documents KCNE1 missense JLNS2 |
| [29037160](https://pubmed.ncbi.nlm.nih.gov/29037160/) | Turkish JLNS families | Oligogenic modifiers (RYR2, NKX2-5); panel utility |
| [18606002](https://pubmed.ncbi.nlm.nih.gov/18606002/) | Congenital LQTS review | Treatment framework (beta-blockers, LCSD, ICD) |

---

## Limitations and Knowledge Gaps

1. **No human molecular-profiling data.** No JLNS2-specific transcriptomic, proteomic, metabolomic, or epigenomic patient datasets were identified. Mechanistic evidence rests on electrophysiology, structural modeling, and animal models.
2. **JLNS2-specific epidemiology is imprecise.** Published prevalence figures aggregate JLNS1+JLNS2; the specific incidence/carrier frequency of *KCNE1*-only JLNS2 is not well quantified.
3. **Mouse cardiac model limitation.** Species differences in dominant repolarizing currents mean *Kcne1⁻/⁻* mice under-represent the human cardiac arrhythmia phenotype [PMID: 19148726]; human iPSC-cardiomyocyte data for JLNS2 specifically are sparse.
4. **gnomAD LoF constraint uncertainty.** *KCNE1*'s single short coding exon yields very few expected LoF events, producing a wide confidence interval around the observed/expected LoF ratio; the "LoF-tolerant" inference should be read with that caveat (though it is congruent with recessive inheritance).
5. **No JLNS2-specific QoL or pharmacogenomic instruments** were identified.

---

## Proposed Follow-up Experiments / Actions

1. **Genotype-stratified natural history.** Analyze registry data to isolate JLNS2 (*KCNE1*) from JLNS1 (*KCNQ1*) and compare event rates, QTc, and treatment response — does the β-subunit subtype modify prognosis?
2. **Patient iPSC-cardiomyocytes.** Generate JLNS2 iPSC-CMs (biallelic *KCNE1* null) to directly measure IKs loss, action-potential prolongation, and drug responses in a human cardiac context, overcoming mouse limitations.
3. **Inner-ear gene therapy translation.** Advance canalostomy *Kcne1* gene delivery [PMID: 33514733] toward larger-animal safety/efficacy and define the developmental window for hearing/vestibular rescue.
4. **Modifier-gene mapping.** Systematically test whether *RYR2*, *NKX2-5*, and common LQTS-modifier polymorphisms explain variable cardiac severity among biallelic *KCNE1* patients [PMID: 29037160].
5. **Standardize perioperative CI protocols.** Prospectively validate a multidisciplinary CI care pathway for JLNS (prophylactic beta-blockade, ICD/pacing standby, avoidance of QT-prolonging anesthetics) across centers to reduce perioperative mortality [PMID: 30227792; PMID: 31846911].
6. **Population screening cost-effectiveness.** Evaluate ECG screening of all congenitally deaf children (especially in consanguineous populations) as a prevention strategy for sentinel sudden death [PMID: 34308870; PMID: 22830134].

---

*Report compiled from primary literature and aggregated genomic resources across a five-iteration autonomous investigation (6 confirmed findings; 27 papers reviewed). Evidence types are noted throughout as human clinical, model organism, in vitro, or computational.*


## Artifacts

- [OpenScientist final report](Jervell_and_Lange-Nielsen_Syndrome_2-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](Jervell_and_Lange-Nielsen_Syndrome_2-deep-research-openscientist_artifacts/final_report.pdf)

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 19 |
| Resolved | 19 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 19 |
| On topic | 14 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 22 |
| Resolved | 20 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 2 |
| Terms whose name was checked | 9 |
| Terms named correctly | 6 |
| Terms named as a **different** term | 3 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `MONDO:0012871` (2 mentions) - the report calls it "MONDO"; MONDO calls it **Jervell and Lange-Nielsen syndrome 2**
- `UBERON:0002282` (1 mention) - the report calls it "organ of Corti"; UBERON calls it **stria vascularis of cochlear duct**
- `UBERON:0002295` (1 mention) - the report calls it "stria vascularis"; UBERON calls it **scala media**

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `ORPHA`.